Evaluation of QT Liability for PF‐05251749 in the Presence of Potential Circadian Rhythm Modification
PF‐05251749 is a dual inhibitor of casein kinase 1 δ/ε, key regulators of circadian rhythm. As a result of its mechanism of action, PF‐05251749 may also change the heart rate corrected QT (QTc) circadian rhythm, which may confound detection of drug‐induced QTc prolongation. In this analysis, a nonli...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | CPT: Pharmacometrics & Systems Pharmacology |
| Online Access: | https://doi.org/10.1002/psp4.12483 |